Therapeutic Induction of Cellular Senescence: Nuclear Matrix in Senescence

Dai Ayusawa

DOI: https://doi.org/10.1007/978-94-017-0669-8_13

2003-01-01

Abstract:Normal human cells stop dividing in culture after a limited number of cell division, a phenomenon termed “replicative senescence” [1]. The senescence is featured most typically by specific morphological alterations, flat and enlarged cell shape, and induction of senescence markers such as fibronectin, collagenase I, and senescence-associated β-galactosidase [2]. It is also shown that in normally senesced human fibroblasts the cyclin-dependent protein kinase inhibitors p21waf1/sdi-1 and p16ink4a, and the tumor suppressor p53 are upregulated or activated, implicating their roles in replicative senescence [3]. Telomere shortening is one of the events in normal human cells [4]. This is thought to be perceived by p53 as a form of DNA damage and result in cell cycle arrest. On the other hand, accumulating data show that normal human cells can enter senescence prematurely upon treatment with various agents or genes, a phenomenon called “premature senescence.” They include, for instance, hydrogen peroxide [5], the activated c-ras gene [6], histone deacetylase inhibitors [7], DNA topoisomerases inhibitors [8], and others. In sharp contrast, they have different effects on immortal cells, namely, having no effect or inducing apoptosis or cell lysis.